Flag of the European Union EU Clinical Trials Register Help

Clinical trials for coated tablet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,751 result(s) found for: coated tablet. Displaying page 34 of 338.
    «« First « Previous 30  31  32  33  34  35  36  37  38  Next» Last»»
    EudraCT Number: 2008-006007-23 Sponsor Protocol Number: STH15195 Start Date*: 2009-12-15
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas
    Medical condition: Soft tissue sarcoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003986-42 Sponsor Protocol Number: Rifa1 Start Date*: 2008-06-18
    Sponsor Name:University Hospital of Tübingen
    Full Title: Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia
    Medical condition: diarrhoea of travellers to South- and Southeast-Asia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021907 Infectious diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003024-46 Sponsor Protocol Number: Repha_1412 Start Date*: 2014-09-19
    Sponsor Name:Repha GmbH
    Full Title: Efficacy, safety and tolerability of Angocin Anti-Infekt N versus Placebo for MRSA eradication
    Medical condition: MRSA colonisation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004017 Bacterial disease carrier PT
    20.0 10021881 - Infections and infestations 10068296 MRSA colonisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020551-31 Sponsor Protocol Number: NBMT-CMV Start Date*: 2004-09-29
    Sponsor Name:Nordic Bone and Marrow Transplantation Group
    Full Title: Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation.
    Medical condition: First cytomegalovirus DNAemia after stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063310 Cytomegalovirus DNA test positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003903-21 Sponsor Protocol Number: INS1007-202 Start Date*: 2019-06-04
    Sponsor Name:Insmed Incorporated
    Full Title: A Randomized, Single-Blind Study to Evaluate the Pharmacokinetics (PK), and Pharmacodynamics (PD) of INS1007 Administered for 12 Weeks in Subjects with Granulomatosis with Polyangiitis (GPA)
    Medical condition: Granulomatosis with Polyangiitis (GPA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001758-89 Sponsor Protocol Number: PSA-ULTRA Start Date*: 2019-08-08
    Sponsor Name:Medical University Graz; Department of Rheumatology and Immunology
    Full Title: Validation of the PsASon ULtrasound scores in patients with psoriatic arthritis undergoing TReatment with Apremilast
    Medical condition: Consecutive patients with PsA and with clinically active peripheral disease (arthritis, tenosynovitis, dactylitis and/or enthesitis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002170-52 Sponsor Protocol Number: 66242 Start Date*: 2019-03-04
    Sponsor Name:VU University Medical Center (VUmc)
    Full Title: TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart failure with preserved ejection fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004116-19 Sponsor Protocol Number: APGELP Start Date*: 2019-04-08
    Sponsor Name:Oslo University Hospital
    Full Title: The AP-GELP Study: A randomized, placebo-controlled clinical trial on the effects of phosphodiesterase 4-inhibitor apremilast in female genital erosive lichen planus
    Medical condition: Genital erosive lichen planus
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004746-28 Sponsor Protocol Number: POR-TAP-16-007 Start Date*: 2017-10-05
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Ticagrelor And PrEconditioning in patients with stable coronaRy artery diSease: a randomized pilot trial (TAPER-S trial)
    Medical condition: Patients with multivessel coronary artery disease requiring staged, ischemia-guided PCI
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10074572 Multiple vessel coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000214-30 Sponsor Protocol Number: P000805 Start Date*: 2017-08-18
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Empagliflozin and its effect on heart failure in type 2 diabetes
    Medical condition: Heart failure and type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001314-25 Sponsor Protocol Number: KIANANDR140701 Start Date*: 2015-03-10
    Sponsor Name:Karolinska Institutet
    Full Title: The effect of on demand versus continuous use of proton pump inhibitors on reflux symptoms, quality of life and self-rated health in patients with gastro-oesophageal reflux disease
    Medical condition: Gastrooesophageal reflux disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003887-39 Sponsor Protocol Number: P1200_46 Start Date*: 2020-10-29
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Molecular effects of Apremilast (Otezal) in synovial biopsies of patients with psoriatic arthisis
    Medical condition: Psoriasis and Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000505-72 Sponsor Protocol Number: 2019-000505-72 Start Date*: 2019-05-13
    Sponsor Name:Transparency in Healthcare
    Full Title: Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT)
    Medical condition: Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006239-44 Sponsor Protocol Number: NL37603.042.11 Start Date*: 2012-10-02
    Sponsor Name:Dutch Childhood Oncology Group
    Full Title: An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED)
    Medical condition: Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004278-40 Sponsor Protocol Number: CA180-597 Start Date*: 2015-11-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
    Medical condition: Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia / Castration-Resistant Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000148-76 Sponsor Protocol Number: 3.0 Start Date*: 2021-08-04
    Sponsor Name:Stockholm Health Care Services
    Full Title: Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial.
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001443-31 Sponsor Protocol Number: 1801 Start Date*: 2018-11-21
    Sponsor Name:Leiden University Medical Center
    Full Title: DOAC Levels prior to Incision study: DALI study
    Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003072-31 Sponsor Protocol Number: 2378 Start Date*: 2018-05-15
    Sponsor Name:VU University Medical Center
    Full Title: The effects of sex hormone administration on marrow and visceral adiposity
    Medical condition: Healthy transgender persons (the effect of differences in sex hormones on the amount of bone marrow fat)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004072-35 Sponsor Protocol Number: 18-AOIP-01 Start Date*: 2019-02-13
    Sponsor Name:CHU de Nice
    Full Title: Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003232 Arteritis coronary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 30  31  32  33  34  35  36  37  38  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 19:06:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA